[1] Xia XY, Wu J, Liu HL, Xia H, Jia B, Huang WX. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. Journal of clinical virology. 2020;127:104360.
[2] Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. Journal of Global Antimicrobial Resistance. 2020;21:22-7.
[3] Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)—An emerging global health threat. Journal of Infection and Public Health. 2020;13:644-6.
[4] WHO. Coronavirus disease 2019 (COVID-19) Situation Report-98. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200427-sitrep-98-covid-19.pdf?sfvrsn=90323472_4. Accessed 27 Apr 2020.
[5] Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. The Journal of infection. 2020. doi: 10.1016/j.jinf.2020.03.062
[6] Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020:102452.
[7] Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen. Archives of academic emergency medicine. 2020;8:e40.
[8] Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal of clinical investigation. 2003;111:1805-12.
[9] Yao Z, Zhang Y, Wu H. Regulation of C-reactive protein conformation in inflammation. Inflammation Research. 2019;68:815-23.
[10] Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19): A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. Clinical infectious diseases. 2020. doi: 10.1093/cid/ciaa443
[11] Sun P, Chen C, Xia Y, Bi X, Liu P, Zhang F, et al. The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma. Disease markers. 2017;2017:6570808.
[12] Wang Q, Song X, Zhao Y, He Q, Shi M, Xu P, et al. Preoperative high c-reactive protein/albumin ratio is a poor prognostic factor of oral squamous cell carcinoma. Future oncology (London, England). 2019;15:2277-86.
[13] Kudou K, Saeki H, Nakashima Y, Kamori T, Kawazoe T, Haruta Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. Journal of gastroenterology and hepatology. 2019;34:355-63.
[14] National Health Commission of the People’s Republic of China. Prevention and control Guideline for COVID-19 (5th edition). http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml. Accessed 8 Feb 2020
[15] Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
[16] Gharebaghi R, Desuatels J, Moshirfar M, Parvizi M, Daryabari SH, Heidary F. COVID-19: Preliminary Clinical Guidelines for Ophthalmology Practices. Medical hypothesis, discovery & innovation ophthalmology journal. 2020;9:149-58.
[17] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology. 2020. doi: 10.1016/j.jaci.2020.04.006.
[18] Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. The Journal of infection. 2020. doi: 10.1016/j.jinf.2020.04.002.
[19] Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of medical virology. 2020. doi: 10.1002/jmv.25819.
[20] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506.
[21] Du Clos TW. C-reactive protein as a regulator of autoimmunity and inflammation. Arthritis Rheum. 2003;48:1475-7.
[22] Yang JR, Xu JY, Chen GC, Yu N, Yang J, Zeng DX, et al. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study. Scientific reports. 2019;9:8143.
[23] Kurokawa Y, Yamashita K, Kawabata R, Fujita J, Imamura H, Takeno A, et al. Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study. Gastric cancer. 2020. doi: 10.1007/s10120-020-01073-5.
[24] Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128-32.
[25] Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection. Clinica chimica acta. 2020;509:91-4.
[26] Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. Journal of medical virology. 2020. doi: 10.1002/jmv.26097.
[27] Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. Journal of clinical gastroenterology. 2005;39:S143-6.
[28] Miura K, Hamanaka K, Koizumi T, Kitaguchi Y, Terada Y, Nakamura D, et al. Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis. Lung cancer (Amsterdam, Netherlands). 2017;111:88-95.
[29] Yu W, Ye Z, Fang X, Jiang X, Jiang Y. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer. Journal of ovarian research. 2019;12:88.
[30] Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. Journal of medical virology. 2020. doi: 10.1002/jmv.26050.
[31] Wada H, Dohi T, Miyauchi K, Doi S, Naito R, Konishi H, et al. Independent and Combined Effects of Serum Albumin and C-Reactive Protein on Long-Term Outcomes of Patients Undergoing Percutaneous Coronary Intervention. Circulation journal. 2017;81:1293-300.
[32] Liu Z, Jin K, Guo M, Long J, Liu L, Liu C, et al. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Annals of surgical oncology. 2017;24:561-8.
[33] Fan Z, Fan K, Gong Y, Huang Q, Yang C, Cheng H, et al. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Cancer Management and Research. 2019;Volume 11:8781-8.
[34] Miyamoto T, Fujitani M, Fukuyama H, Hatanaka S, Koizumi Y, Kawabata A. The C-Reactive Protein/Albumin Ratio is Useful for Predicting Short-Term Survival in Cancer and Noncancer Patients. Journal of Palliative Medicine. 2019;22.